FIELD: medicine.
SUBSTANCE: method involves applying IAG-laser treatment to exudates fixation region. Then, drug mixture is additionally introduced into lymphatic orbit region. The mixture has Lidocaine 20-40 mg, Dalargin 1-2 mg, Mexidol 50-100 mg, Lidase 16-32 units, Hemase 3000-5000 IU. The drug mixture is introduced into the lymphatic orbit region daily by carrying out pterygopalatine block on the same side with the injured eye with 3-5 blocks in a course.
EFFECT: accelerated postoperative rehabilitation; accelerated exudates destruction; arrested inflammatory process with drug mixture.
3 cl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING CATARACT IN PATIENTS WITH PSEUDOEXFOLIATION SYNDROME | 2013 |
|
RU2515550C1 |
METHOD OF TREATING FIBRINOID SYNDROME AFTER CATARACT EXTRACTION WITH IMPLANTATION OF INTRAOCULAR LENS | 2009 |
|
RU2414194C1 |
METHOD FOR TREATING EARLY EXUDATIVE COMPLICATIONS OF FISTULIZING ANTIGLAUCOMA OPERATIONS | 2001 |
|
RU2198632C2 |
METHOD FOR TREATING PATIENTS FOR RECURRENT UVEITIS | 2005 |
|
RU2299065C1 |
METHOD FOR REVEALING NOT VISUALIZED FIBRINOUS EXUDATE IN THE MOISTURE OF THE FORWARD CHAMBER OF THE EYE | 2005 |
|
RU2297857C2 |
METHOD FOR COMPLEX TREATMENT OF ENDOGENOUS UVEITIS FOLLOWED BY MACULAR EDEMA | 2016 |
|
RU2635083C1 |
METHOD FOR THE TREATMENT OF OPTIC NEUROPATHY IN PATIENTS WITH EDEMATOUS EXOPHTHALMOS | 2020 |
|
RU2742188C1 |
METHOD FOR TREATING DIABETIC RETINOPATHY | 2004 |
|
RU2270025C1 |
METHOD FOR TREATING PRIMARY OPEN ANGLE GLAUCOMA | 2006 |
|
RU2320308C1 |
PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC AND FIBRINOLYTIC EFFECT | 2002 |
|
RU2216348C1 |
Authors
Dates
2006-12-27—Published
2005-06-28—Filed